ClinicalTrials.gg
CompletedNCT06115174CRC - PTXUpdated Oct 21, 2026

Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer

A Phase 4 interventional study of Pentoxifylline and FOLFOX in Metastatic Colorectal Carcinoma, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Tanta University · Phase 4, Interventional, and Other

How we know

Updated Oct 21, 2026Now CompletedFirst site in Egypt+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Colorectal Neoplasms with a site in Egypt — 15 open to participants now, 17 under way, 5 of them phase 3. Colorectal Neoplasms · Egypt.

Enrollment
24th of 31
44 · median 60
Started
2024
with 4 others
Phase 4
Only one
of the 55
Registered
30th of 55
by date
Lead sponsor
7 of 55
Tanta University

Among the 55 studies in Colorectal Neoplasms with a site in Egypt, this one is the 24th largest by enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2024, is the only one in phase 4, and was the 30th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 55 studies in Colorectal Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Colorectal Neoplasms with a site in Egypt, or all of them as a file.
02

Study summary

The aim of this work is to assess the antitumor effect of Pentoxiphylline in patients with metastatic colorectal cancer receiving stomatal chemotherapy ± targeted therapy.

Read the detailed description

Colorectal cancer (CRC) ranks as the third most common cancer globally and second in terms of mortality. Although CRC incidence rates are higher in high-income compared with low-to-middle-income countries (LMICs), mortality is higher in LMICs. And although more than 90% of CRC cases are diagnosed in individuals over age 55, CRC incidence is rising in younger populations. For example, Egypt, Saudi Arabia, the Philippines, and Iran have CRC incidence rates in individuals under age 40 of 38%, 21%, 17%, and 15%-35%, respectively. This is compared with only 2%-8% of new cases in the U.S. and the European Union in individuals in this age bracket. Along with the high incidence rate of CRC in individuals under age 40 in Egypt, CRC is diagnosed at more advanced stages in these younger Egyptians. CRC survival is highly dependent upon the stage of disease at diagnosis and typically ranges from a 90% 5-year survival rate for cancers detected at the localized stage to 14% for individuals diagnosed with distant metastatic cancer.

Apoptosis may occur via two major interconnected pathways: the extrinsic or death receptor-mediated pathway, which is activated by the binding of specific ligands (such as FasL, TNF-α and TRAIL) to the receptors of cell surfaces; and the intrinsic or mitochondrial-mediated pathway, which is regulated through proteins of the Bcl-2 family and triggered either by the loss of growth factor signals or in response to genotoxic stress. Therefore the replication of cells with DNA damage is generally avoided because harmful genomic alterations typically induce the activation of apoptosis. It has been widely accepted that alterations in the physiologic response to DNA damage can facilitate the accumulation of oncogenic mutations; this accumulation may eventually lead to the development of neoplasia.

Angiogenesis is a complex process by which new blood vessels are formed from endothelial precursor. It is a critical step in cancer progression and is considered one of the hallmarks of cancer. This process is mediated through a group of ligands and receptors that work in tight regulation. A group of glycoproteins, including the VEGFs (VEGF-A, VEGF-B, VEGF-C, and VEGF-D) and the placental growth factor (PIGF), act as effectors of angiogenesis. These factors interact with three VEGF receptors (VEGFR- 1, VEGFR-2, and VEGFR-3) and two neuropilin co-receptors (NRP1 and NRP2). The VEGF-A gene consists of eight exons with splice variants forming different isoforms, namely, VEGFA121, VEGFA165, VEGFA189, and VEGFA209; VEGFA165 is the most biologically active of these isoforms [14]. The VEGFRs are tyrosine kinase receptors that are primarily located in the vascular endothelial cells. The binding of VEGF-A to VEGFR-2 is believed to be the most important activator of angiogenesis.

Pentoxifylline (PTX) is a methylxanthine derivative that is commercially available in the name of Trental. It is currently used for management of peripheral vascular diseases. Its postulated mechanism of action is thought to be mediated through reducing blood viscosity and enhancing RBCs flexibility. However, it has been shown that PTX also may potentially be used in the anticancer therapy.

The studies demonstrated the potential effects of pentoxifylline on angiogenesis inhibition. It can affect the release and function of some predominantly proangiogenic vascular endothelial growth factors. Specifically, the release of the VEGF family of pro-angiogenesis factors (notably VEGF-A and VEGF-C) [16]. Furthermore, the mechanism by which pentoxifylline inhibits angiogenesis may be through the inhibition of activation of STAT3 which contributes to tumor cell survival by regulating the expression of metastatic genes, MMPs, serine protease uPA and potent angiogenic genes.

In addition, PTX has also the ability to induce apoptosis and potentiate the apoptotic effects of chemotherapy in several cancer types, one major mechanism is through activation of the caspase-dependent apoptosis that is accompanied by a decrease in kappa B-alpha- phosphorylation and up-regulation of the pro-apoptotic genes Bax, Bad, Bak, and caspases- 3,

-8, and -9.

03

Conditions studied

  • Metastatic Colorectal Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with histologically and/or radiologically confirmed diagnosis of colorectal carcinoma.
  • Both genders.
  • Age ≥ 18 years old, and ≤ 75 years old.
  • Performance status 0-1 according to the (ECOG).
  • Patients with adequate hematologic parameters (white blood cell count

    ≥3000/mm3, granulocytes ≥1500/mm3, ≥100,000/mm3, ≥ 8 gm/l).

  • Patients with adequate renal functions (serum creatinine ≤1.5 mg/dL).
  • Patients with adequate hepatic functions ( ≤1.5 mg/dL or albumin ≥3 g/dL).

Exclusion criteria

Exclusion Criteria:

  • Patients with active liver diseases (chronic viral hepatitis, hepatitis, alcoholic hepatitis, Wilson's disease, hemochromatosis, or cirrhosis).
  • Patients with .
  • Patients with active infection.
  • Patients on chronic use of .
  • Patients receiving blood thinning agents(aspirin, clopidogrel, warfarin)
  • Patients with other (synchronous, or metachronous)
  • Prior exposure to neurotoxic drugs (oxaliplatin, cisplatin, vincristine, paclitaxel, or docetaxel, INH) for at least 6 months prior the study treatment.
  • Evidence of pre-existing peripheral neuropathy resulting from another reason (diabetes, brain tumor, brain trauma, , thyroid disorder).
  • Patients with diabetes and other conditions that predispose to neuropathy as hypothyroidism, autoimmune diseases, hepatitis C.
  • History of known allergy to oxaliplatin or other platinum agents.
  • Patients with moderate and severe renal impairment ( \<50 ml/min) or serum creatinine >1.5 mg/dl.
  • Pregnant and breastfeeding women.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Other
    People not recieving the drug

    (Control group; n=22) which will receive FOLFOX (leucovorin, fluorouracil, oxaliplatin) or XELOX (oxaliplatin + capecitabine) ± target therapy (Bevacizumab).

    Radiation: FOLFOX · Radiation: XELOX · Drug: Monoclonal antibodies (target therapy)

  • Active comparator
    People recieving the drug

    (Pentoxiphylline group; n=22) which will receive the same FOLFOX (leucovorin, fluorouracil, oxaliplatin) or XELOX regimen (oxaliplatin + capecitabine) ± target therapy (Bevacizumab) in addition to Pentoxiphylline 400 mg twice daily.

    Drug: Pentoxifylline · Radiation: FOLFOX · Radiation: XELOX · Drug: Monoclonal antibodies (target therapy)

Interventions

  • Pentoxifylline (PTX) is a methylxanthine derivative that is commercially available in the name of Trental. It is currently used for management of peripheral vascular diseases. Its postulated mechanism of action is thought to be mediated through reducing blood viscosity and enhancing RBCs flexibility. However, it has been shown that PTX also may potentially be used in the anticancer therapy \[15\]. The studies demonstrated the potential effects of pentoxifylline on angiogenesis inhibition. It can affect the release and function of some predominantly proangiogenic vascular endothelial growth factors. Specifically, the release of the VEGF family of pro-angiogenesis factors (notably VEGF-A and VEGF-C) \[16\]. Furthermore, the mechanism by which pentoxifylline inhibits angiogenesis may be through the inhibition of activation of STAT3 which contributes to tumor cell survival by regulating the expression of metastatic genes, MMPs, serine protease uPA and potent angiogenic genes \[17\].

  • RadiationFOLFOX

    (leucovorin, fluorouracil, oxaliplatin)

  • RadiationXELOX

    (oxaliplatin + capecitabine)

  • DrugAntibodies, MonoclonalStudies of Antibodies, MonoclonalAntibodies, Monoclonal pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    target therapy (Bevacizumab).

06

What researchers measure

Primary outcomes

  1. Comparison of RECIST between the two groups.

    Difference in response rate (RECIST) between the control and drug groups.

    Time frame: one year

  2. Change in the serum concentration of the measured biological markers.

    Time frame: one year

  3. Difference in progression free survival 'PFS' between the two groups

    Time frame: One year.

  4. Difference in overall survival 'OS' between the two groups.

    Time frame: One year.

07

Study locations

1 site
  • Tanta University
    Tanta, Gharbia Governorate 31511, Egypt
08

References and documents

Publications

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. PubMed 30207593 ↗
  • Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018 Nov;103:356-387. doi: 10.1016/j.ejca.2018.07.005. Epub 2018 Aug 9. PubMed 30100160 ↗
  • Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017 Apr;66(4):683-691. doi: 10.1136/gutjnl-2015-310912. Epub 2016 Jan 27. PubMed 26818619 ↗
  • Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, Kuipers EJ. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015 Oct;64(10):1637-49. doi: 10.1136/gutjnl-2014-309086. Epub 2015 Jun 3. PubMed 26041752 ↗
  • Sankaranarayanan R. Screening for cancer in low- and middle-income countries. Ann Glob Health. 2014 Sep-Oct;80(5):412-7. doi: 10.1016/j.aogh.2014.09.014. PubMed 25512156 ↗
  • Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009 Nov;22(4):191-7. doi: 10.1055/s-0029-1242458. PubMed 21037809 ↗
  • Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016 Sep 30;7(3):105-114. eCollection 2016. PubMed 27766137 ↗
  • Vuik FE, Nieuwenburg SA, Bardou M, Lansdorp-Vogelaar I, Dinis-Ribeiro M, Bento MJ, Zadnik V, Pellise M, Esteban L, Kaminski MF, Suchanek S, Ngo O, Majek O, Leja M, Kuipers EJ, Spaander MC. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut. 2019 Oct;68(10):1820-1826. doi: 10.1136/gutjnl-2018-317592. Epub 2019 May 16. PubMed 31097539 ↗
  • Abou-Zeid AA, Khafagy W, Marzouk DM, Alaa A, Mostafa I, Ela MA. Colorectal cancer in Egypt. Dis Colon Rectum. 2002 Sep;45(9):1255-60. doi: 10.1007/s10350-004-6401-z. PubMed 12352245 ↗
  • Gado A, Ebeid B, Abdelmohsen A, et al. Colorectal cancer in Egypt is commoner in young people: Is this cause for alarm? Alexandria J Med. 2014; 50:197-201.
  • Metwally IH, Shetiwy M, Elalfy AF, et al. Epidemiology and survival of colon cancer among Egyptians: A retrospective study. J Coloproctol. 2018;38:24-29.
  • American Cancer Society: Treatment of Colon Cancer, by Stage. 2020. Available at https://www.cancer.org/cancer/colon-rectal-cancer/ treating/by-stage- colon.html.
  • Alcaide J, Funez R, Rueda A, Perez-Ruiz E, Pereda T, Rodrigo I, Covenas R, Munoz M, Redondo M. The role and prognostic value of apoptosis in colorectal carcinoma. BMC Clin Pathol. 2013 Oct 10;13(1):24. doi: 10.1186/1472-6890-13-24. PubMed 24106912 ↗
  • Mousa L, Salem ME, Mikhail S. Biomarkers of Angiogenesis in Colorectal Cancer. Biomark Cancer. 2015 Oct 27;7(Suppl 1):13-9. doi: 10.4137/BIC.S25250. eCollection 2015. PubMed 26543385 ↗
  • Meirovitz A, Baider L, Peretz T, Stephanos S, Barak V. Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I). Tumour Biol. 2021;43(1):341-349. doi: 10.3233/TUB-211533. PubMed 34957976 ↗
  • Khoury W, Trus R, Chen X, Baghaie L, Clark M, Szewczuk MR, El-Diasty M. Parsimonious Effect of Pentoxifylline on Angiogenesis: A Novel Pentoxifylline-Biased Adenosine G Protein-Coupled Receptor Signaling Platform. Cells. 2023 Apr 20;12(8):1199. doi: 10.3390/cells12081199. PubMed 37190108 ↗
  • Dhumale P, Nikam Y, Gude R. Pentoxifylline: A potent inhibitor of angiogenesis via blocking STAT3 signaling in B16F10 melanoma. Int J Tumor Ther. 2013 ;2:1-9.
  • Al-Husein BA, Mhaidat NM, Alzoubi KH, et al. Pentoxifylline induces caspase- dependent apoptosis in colorectal cancer cells. Inform Med Unlocked. 2022;31:100997
  • Cuituny-Romero AK1, Onofre-Castillo J. Radiological evaluation, with RECIST criteria of treatment response of non-microcytic lung cancer. Anales de Radiologia México. 2015;14:31-42.

Individual participant data

Plan to share: Yes

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jun 2026, 28 months.

Of 38 phase 4 interventional studies under Colorectal Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 57. This study's 28 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Nov 2023 → Feb 2024, primary completion Nov 2024 → Jun 2026 and completion Dec 2024 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2023
First posted
Nov 2, 2023
StartActual
Feb 1, 2024was Nov 2023
Primary completionActual
Jun 1, 2026was Nov 2024
CompletionActual
Aug 1, 2026was Dec 2024
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 21, 2026
Sites
1 site added — first site in Egypt
Show site
  • Tanta University · Tanta, Egypt
Oct 21, 2026
Start date
Nov 1, 2023→Feb 1, 2024 (actual)
Oct 21, 2026
Primary completion
Nov 1, 2024→Jun 1, 2026 (actual)
Oct 21, 2026
Study completion
Dec 1, 2024→Aug 1, 2026 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Completed
    1 site added — first site in Egypt
    Show site
    • Tanta University · Tanta, Egypt
    Start date Nov 1, 2023→Feb 1, 2024 (now actual)
    Primary completion Nov 1, 2024→Jun 1, 2026 (now actual)
    Study completion Dec 1, 2024→Aug 1, 2026 (now actual)
    + 5 other changes: verification date, oversight details, contact details, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06115174
Lead sponsor
Tanta University
Responsible party
Nada Abu Eleneen Darwiesh Ibrahim (Bachelor of Clinical Pharmacy (2021) - Faculty of Pharmacy - Mansoura University, Tanta University) — Principal investigator
First posted
Nov 2, 2023
Start date
Feb 1, 2024
Primary completion
Jun 1, 2026
Completion
Aug 1, 2026
Last update
Oct 21, 2026

Study contacts

Tarek Mohammed, Professor
study chair · Tanta University
Dalia Refaat, Assistant Professor
study chair · Tanta University
Sherif Refaat, Lecturer
study chair · Oncology Centre - Faculty of Medicine - Mansoura University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pentoxifylline

Start the discussion